(Q47376049)

15 January 2018

title

Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer (English)

1 reference

15 January 2018

author name string

A Pennycuick

1

1 reference

15 January 2018

T Simpson

2

1 reference

15 January 2018

D Crawley

3

1 reference

15 January 2018

R Lal

4

1 reference

15 January 2018

G Santis

5

1 reference

15 January 2018

P Cane

6

1 reference

15 January 2018

K Tobal

7

1 reference

15 January 2018

J Spicer

8

1 reference

15 January 2018

publication date

1 August 2012

1 reference

15 January 2018

International Journal of Clinical Practice

published in

1 reference

15 January 2018

volume

66

1 reference

15 January 2018

issue

8

1 reference

15 January 2018

page(s)

748-752

1 reference

15 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

KRAS mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

Screening for EGFR mutations in lung cancer, a report from India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

Mutations and response to epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02961.X

10.1111/J.1742-1241.2012.02961.X

21 January 2018

Identifiers

DOI

1 reference

15 January 2018

1 reference

15 January 2018